| |
Prescription opioid dispensing patterns among patients with schizophrenia or bipolar disorder.
Roy BD, Li J, Lally C, Akerman SC, Sullivan MA, Fratantonio J, Flanders WD, Wenten M
BMC Psychiatry. 2024 Apr 2;24(1):244. doi: 10.1186/s12888-024-05676-5. Epub 2024 Apr 2.
PMID: 38566055 A Cross-Sectional Study on the Associations between Economic, Social, and Political Resources and Subjective Caregiver Burden among Older Spousal Caregivers in Two Nordic Regions.
Åkerman S, Nyqvist F, Nygard M
Nurs Rep. 2023 Feb 27;13(1):365-377. doi: 10.3390/nursrep13010034. Epub 2023 Feb 27.
PMID: 36976686 Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.
Correll CU, Stein E, Graham C, DiPetrillo L, Akerman S, Stanford AD, Jiang Y, Yagoda S, McDonnell D, Hopkinson C
Schizophr Bull. 2023 Mar 15;49(2):454-463. doi: 10.1093/schbul/sbac144.
PMID: 36305696 Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine.
McIntyre RS, Citrome L, Cummings H, Todtenkopf MS, Tan LA, White M, Akerman S
CNS Spectr. 2023 Jun;28(3):288-299. doi: 10.1017/S1092852922000116. Epub 2022 Mar 3.
PMID: 35236531 Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.
Mannelli P, Douaihy AB, Akerman SC, Legedza A, Fratantonio J, Zavod A, Sullivan MA
Am J Addict. 2022 Mar;31(2):142-147. doi: 10.1111/ajad.13264. Epub 2022 Feb 9.
PMID: 35137481 Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.
Shulman M, Hu MC, Sullivan MA, Akerman SC, Fratantonio J, Barbieri V, Nunes EV, Bisaga A
Drug Alcohol Depend. 2022 Apr 1;233:109343. doi: 10.1016/j.drugalcdep.2022.109343. Epub 2022 Feb 2.
PMID: 35131528 Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone.
Mannelli P, Douaihy AB, Zavod A, Legedza A, Akerman SC, Sullivan MA
Am J Drug Alcohol Abuse. 2021 Nov 2;47(6):753-759. doi: 10.1080/00952990.2021.1969659. Epub 2021 Nov 9.
PMID: 34752714 The Expert Caregiver Intervention Targeting Former Caregivers in Finland: A Co-Design and Feasibility Study Using Mixed Methods.
Åkerman S, Nyqvist F, Coll-Planas L, Wentjarvi A
Int J Environ Res Public Health. 2021 Sep 27;18(19) doi: 10.3390/ijerph181910133. Epub 2021 Sep 27.
PMID: 34639437 Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018.
Jain P, McKinnell K, Marino R, Vunnava P, Liles-Burden MA, Desai A, Wenten M, Fratantonio J, Akerman SC, Sullivan MA, Bloomgren G
Drug Saf. 2021 Mar;44(3):351-359. doi: 10.1007/s40264-020-01020-4. Epub 2020 Nov 30.
PMID: 33258068 Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.
Kosten T, Aharonovich E, Nangia N, Zavod A, Akerman SC, Lopez-Bresnahan M, Sullivan MA
Addict Behav. 2020 Dec;111:106538. doi: 10.1016/j.addbeh.2020.106538. Epub 2020 Jul 3.
PMID: 32777606 View more publications on PubMed |